International Journal of Molecular Sciences - J-STAGE Home

Biological and Pharmaceutical Bulletin Advance Publication by J-STAGE DOI:10.1248/bpb.b15-00331

Ⓒ 2015 The Pharmaceutical Society of Japan

Advance Publication September 4, 2015

Biol. Pharm. Bull. Regular Article

Epigallocatechin-3-gallate (EGCG) suppresses the trafficking of lymphocytes to epidermal

melanocytes via inhibition of JAK2: Its implication for vitiligo treatment

Weixuan Ninga，Suiquan Wang

b，Xiaowu Dongc， Dongyin Liu

b, Lifang Fu

b, Rong Jin

b，

Aie Xub,

*

Affiliation

aDepartment of Dermatology, Guangxing Affiliated Hospital of Zhejiang Chinese Medical University,

Hangzhou, Zhejiang 310007, P.R. China bDepartment of Dermatology, Third People’s Hospital of Hangzhou, Hangzhou 310009, P.R. China

cZJU-ENS Joint Laboratory of Medicinal Chemistry, Zhejiang Province Key Laboratory of Anti-

Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou,

310058, P. R. China

*Correspondence

Dr. Aie Xu, Department of Dermatology, Third People’s Hospital of Hangzhou, Hangzhou 310009,

P.R. China. E-Mail: [email protected]; Tel.: +86 571 87827535; Fax: +86 571 87814481.

Abstract

Vitiligo is an inflammatory skin disorder in which activated T cells play an important role in

its onset and progression. Epigallocatechin-3-gallate (EGCG), the major chemical

constituent of green tea, exhibits remarkable anti-oxidative and anti-inflammatory properties.

EGCG administration has been confirmed to decrease the risk of vitiligo; however, the

underlying mechanism is undetermined. In this study, we proved that EGCG directly

inhibited the kinase activity of Janus kinase 2 (JAK2). In primary cultured human

melanocytes, EGCG pre-treatment attenuated IFN-γ-induced phosphorylation of JAK2 and

its downstream STAT1 and STAT3 in a dose-dependent manner. We further examined the

chemoattractant expression in melanocytes and demonstrated that EGCG significantly

inhibited IFN-γ-induced expression of ICAM-1, CXCL10, and MCP-1 in human

melanocytes. In addition, EGCG reduced the protein levels of the corresponding receptors

including CD11a, CXCR3, and CCR2 in human T lymphocytes. As a consequence, adhesion

of human T cells to melanocytes induced by IFN-γ was effectively suppressed by EGCG.

Taken together, our results provided new evidence for the effectiveness of EGCG in vitiligo

treatment and supported JAK2 as a molecular target for vitiligo medicine development.

Key words

vitiligo; Epigallocatechin-3-gallate; melanocyte; Janus kinase 2; chemoattractant

Biological and Pharmaceutical Bulletin Advance Publication

Introduction

Vitiligo is a depigmentation disorder caused by the destruction of epidermal melanocytes [1]. The exact

pathophysiological mechanism of vitiligo remains elusive. However, several hypotheses, including

autoimmune, oxidant-antioxidant, genetic susceptibility, neural and viral mechanisms, have been

proposed to explain the selective destruction of melanocytes. Currently, clinical and bench findings

suggest the major role of autoimmune factors in the progress of vitiligo. Inflammatory cells, mostly T

lymphocytes, have been identified close to vitiligous skin lesion [2, 3]. Lesional CD8+ T cells specially

induce melanocyte apoptosis in unaffected skin ex vivo, and the frequency of anti-melanocyte CD8+ T

cells in both the blood and skin of vitiligo patients correlates with the severity of disease [4, 5]. Moreover,

immunosuppressive therapies targeting T-cell activation have been shown to be effective for vitiligo

treatment [6, 7]. These evidences all support a direct role for T lymphocytes in melanocyte destruction

in human vitiligo.

EGCG, a major catechin in green tea, is considered beneficial for human health, especially as ananti-

oxidative agent[8]. In addition, EGCG was confirmed to directly inhibit protein kinases by working as

an ATP analog [9]. Previously, we reported the therapeutic effect of EGCG in vitiligo induced by

monobenzone in mice [10]. Our results suggested that it could contribute to the suppression of CD8+ T

cell migration and the inflammatory cytokine expression. However, the mechanism regarding the EGCG

regulation of immune responses in vitiligo is still unclear.

The aim of study is to elucidate the inhibitory effects of EGCG on inflammatory signaling pathways and

to identify the target of EGCG inhibition.

Results and Discussion

EGCG inhibited Jak2 kinase activity in vitro

The JAKs are a family of four non-receptor tyrosine kinases including JAK1, JAK2 JAK3 and TYK2.

Recruitment of stimuli to cell surface receptors activates JAKs which, in turn, phosphorylates and


stimulates latent cytoplasmic STAT proteins to an active dimer, leading to nuclear translocation and

DNA binding and subsequently modulating gene transcription [11]. The JAK/STAT signal pathway

controls a number of important biological responses, including immune functions, cellular growth,

cellular differentiation and hematopoiesis. Dysregulation of JAK signaling has been identified in

multiple autoimmune disorders [12]. Due to their ability to selectively modulate immune function,

targeted JAK inhibitors are attractive candidates for some skin diseases such as psoriasis and atopic

dermatitis [13-15].

Our computer simulation result suggested that EGCG may bind to JAK2 protein (Fig. 1C). To determine

the effect of EGCG binding on JAK2 kinase activity, EGCG and its derivative, peracetylated EGCG

(AcEGCG, Fig. 1A) were tested by Caliper mobility shift assay, along with the pan-kinase inhibitor

Staurosporine (STS) as the positive control. The results showed that EGCG inhibited the kinase activity

of JAK2 with the IC50 at 18.85nM. While, peracetylated EGCG with the all the hydroxyl groups

substituted showed much higher IC50 for JAK2 inhibition (2126nM) (Fig. 1B). These results indicated

that EGCG could bind to JAK2 and directly inhibited its kinase activity.

EGCG inhibited IFN-γ-induced phosphorylation of JAK2, STAT1 and STAT3 in human melanocytes

Various cytokines elicit their biological effects through the activation of JAK-STAT pathways [16, 17].

To characterize the inhibition of JAK2 activity in melanocytes, we examined the cellular

phosphorylation levels of JAK1, JAK2, STAT1 and STAT3 in human melanocytes after treatment with

IFN-γ and EGCG. It was shown that while IFN-γ increased the phosphorylation of JAK2, STAT1 and

STAT3, EGCG suppressed the upregulation of protein phosphorylation in response to IFN-γ in a dose-

dependent manner (Fig. 2). In terms of JAK1, its phosphorylation level wasn’t changed upon IFN-γ

stimulation, but slightly increased after EGCG treatment. It is then suggested that EGCG specifically

targets JAK2 in JAK-STAT pathway.

Various studies have supported a critical role of IFN-γ in vitiligo development [4, 18, 19]. In vitiligo

patients and animal models, IFN-γ level is significantly elevated in lesional skin [4,20]. IFN-γ signaling

regulates the expression of cytokine as well as adhesion molecules facilitating the lymphocyte migration


[16, 24]. So that, local IFN-γ release promotes further recruitment of melanocyte-specific CD8+ T cells

into the vitiligo lesion [21]. Moreover, our previous study proved that IFN-γ directly caused apoptosis

and senescence in melanocytes, and induced melanocyte to secret autoimmune enhancers including IL-

6 and HSP70 [18]. Since IFN-γ mainly engages JAK-STAT pathways to achieve its biological effects,

blocking IFN-γ signaling via the inhibition of JAK2 activity could be a promising therapeutic approach

to prevent vitiligo development.

EGCG inhibited the production of chemoattractants

Increased level of chemoattractants including ICAM-1 and CXCL10 has been found in the skin lesions

of vitiligo patients. [2, 22-24]. To further address the effects of EGCG on the expression of

chemoattractants, we measured the expression levels of ICAM-1 and CXCL10, as well as MCP-1 which

is also implicated in the pathogenesis of certain autoimmune diseases [25, 26]. The results showed that

IFN-γ stimulation significantly increased the mRNA expression and protein secretion of ICAM-1,

CXCL10, and MCP-1. Compared with the IFN-γ stimulation group, EGCG pretreatment significantly

suppressed the IFN-γ-induced production of ICAM-1, CXCL10, and MCP-1 in a dose-dependent

manner. As a positive control, the JAK2-specific kinase inhibitor AG490 also inhibited the induction of

ICAM-1, CXCL10 and MCP-1 by IFN-γ (Fig.3).

Chemoattractants are involved in the attraction and activation of leukocytes during the inflammatory

process. ICAM-1, which can be expressed on the cellular membrane or secreted into extracellular matrix,

is a ligand for leukocyte adhesion protein LFA-1. ICAM-1 promotes the leukocyte trans-endothelial

migration as well as the localization of leukocyte to target cells [24, 23]. MCP-1 was also suggested to

mediate lymphocyte migration [27]. CXCL10 engagement is responsible for the stimulation of

monocytes and the migration of NK and T-lymphocytes. CXCL10 was elevated in both vitiligo patient

skin and serum. Due to the critical roles of these molecules in the skin homing of leukocytes, it is

reasonable to presume them as targets for vitiligo treatment. In fact, application of CXCL10-neutralizing


antibody has been proven to remarkably decrease the development of depigmentation in a mouse model

of vitiligo [24].

It is notable that the expression of T cell chemoattractants is also controlled by other cytokines. For

example, IL-6 could create a MCP-1-gradient, and increase the expression of ICAM-1, functional to

inflammatory cells chemotaxis [28-31]. As we have mentioned above, many cytokines elicit their

biological effects through the activation of JAK-STAT pathways including IL-6 [28]. JAK2 inhibition

by EGCG treatment simultaneously blocks the signaling from various cytokines and maximizes the

effect on the blockage of chemoattractant expression. On the other side, the inhibition of chemoattractant

expression by EGCG was more potent than that by AG490 treatment, suggesting that EGCG may work

via other mechanism besides targeting JAK2 to achieve that effect.

EGCG inhibited the production of chemoattractant receoptors in T lymphocytes

CXCR3 and CCR2 are the receptors to CXCL10 and MCP-1, respectively. CD11a is one of the

molecules that form LFA-1 which is the receptor of ICAM-1. Levels of CXCR3 and CD11a were

elevated on autoreactive lymphocytes in both human vitiligo patients and vitiligo models. In addition,

CXCR3 was demonstrated to be essential for autoreactive T cell accumulation in the skin and subsequent

depigmentation in a mouse model, implicating this chemokine pathway as functionally required for

vitiligo [24, 32]. We then evaluated the effect of EGCG on the expression of CD11a, CXCR3, and CCR2

in activated human T cells. Western blot analysis revealed that EGCG treatment for 24 h decreased the

expression of CD11a, CXCR3, and CCR2 in Jurkat, a CD4+T leukemia cell line, in a dose-dependent

manner (Fig. 4A). In purified CD8+T cells from PBMC, EGCG inhibited the expression of those

receptors as well (Fig. 4B). Comparatively, AG490 also inhibited the expression of CD11a, CXCR3,

and CCR2, suggesting that the inhibiting effect of EGCG on chemoattractant receptor induction was at

least partially through the inhibition of JAK2 activity.

Suppression of T lymphocyte adhesion to melanocytes by EGCG treatment


Given the importance of CXCL10/CCR3 and ICAM-1/LFA-1 for lymphocyte migration and adhesion,

we further examined the effects of EGCG on the adhesion of T lymphocytes to melanocytes. In our study,

treatment of human melanocytes monolayers for 24 h with 200U/mL IFN-γ resulted in a 5.7-fold (Jurkat

cells, Fig. 5A) and 6.3-fold (CD8+T cells, Fig. 5B) increase of T lymphocyte adhesion. In comparison,

IFN-γ-induced T cell adhesion was strongly suppressed when both T cells and melanocytes were pre-

treated with 40 µM EGCG (Fig. 5A and 5B, the far right column). Furthermore, EGCG treatment of T

cells or melanocytes alone also decreased the adhesion between T lymphocytes and melanocytes, which

is consistent with the above results showing that the expression of chemoattractants and their receptors

were all inhibited by EGCG,.

Adhesion to target cells is the initial and necessary step for T lymphocytes to exert their functions.

Adhesion molecules such as ICAM-1 and its receptors LFA-1 are crucial for immune synapse formation,

antigen presentation [33] and lymphocyte killing [34, 35]. It has been reported that adhesion defect in

CD8+T lymphocytes, which is caused by a combination of decreased cell surface levels of adhesion

molecules, deficient LFA-1 activation, and the failure to recruit essential adhesion receptors to the

membrane contact site formed with cognate target cells, weakens their capacity of cytolysis [36].

Therefore, EGCG-caused compromise of interaction between T lymphocytes and melanocytes will

profoundly weaken the T lymphocyte activation and decrease the cytolysis of melanocytes by CD8+CTL.

Collectively, EGCG inhibited the chemoattractant expression in melanocytes and the expression of the

corresponding receptors in T lymphocytes via directly targeting JAK2 kinase, leading to the decrease of

lymphocyte migration/accumulation in vitiligo lesion as well as the weakening of T cell adhesion to

melanocytes. The overall effects will be less activation of auto-reactive T lymphocytes and less

destruction of melanocytes. Our study provides insights into the effects of EGCG on inflammation in

vitiligo and elucidates JAK2 as its novel anti-inflammatory target. Further investigations should be

carried out to further clarify the JAK2 as an independent anti-inflammatory drug target in vitiligo therapy.

Materials and methods

Reagents


EGCG, DMSO, EDTA, Phorbol 12-Myristate 13-Acetate (PMA), Ionomycin, Human recombinant IFN-

γ and IL-2 were obtained from Sigma (St. Louis, USA). F12 medium, RPMI-1640 medium, penicillin,

streptomycin, L-gultamine, and fetal bovine serum (FBS) were purchased from Thermo Fisher Scientific

(Carlsbad, CA, USA). Ficoll-Paque was obtained from GE Healthcare (Little Chalfont, UK). Human

CD8+ T Cell Isolation Kit was purchased from MiltenyiBiotec (Cologne, Germany). All antibodies for

Western blotting were purchased from Cell Signaling Technology (Danvers, MA, USA).

Computer analysis of JAK2-EGCG binding

The molecular docking was performed by using LigandFit module embedded in Discovery Studio 2.5.29

At first, the crystal structure of JAK-2 was obtained from PDB bank (entry code: 4GMY), and then was

removed water molecules and charged by CHARMm force field. The binding site was derived from the

volume of co-crystal ligand. For generation of the ligands’ conformations, variable numbers of Monte

Carlo simulations were employed. All the calculations during the docking steps were performed under

the PLP energy grid. A short rigid body minimization was then performed and 50 preferable poses were

saved according to their dock score. Based on the dock score and visual inspection, the most possible

pose was selected for the further analysis.

In vitro kinase assays

Inhibition of EGCG and peracetylated EGCG (AcEGCG) on JAK2 kinase activity was tested in

Shanghai Chempartner Co., LTD (Shanghai, China). EGCG and AcEGCG were tested in duplicate for

10 concentrations. Samples were analyzed by Caliper mobility shift assay using LabChip 3000 (Caliper

Life Sciences, MA, USA). Data was analyzed using HTS Well Analyzer Software from Caliper Life

Sciences to determine IC50.

Cell isolation and culture

Methods for the isolation and cultivation of primary normal melanocytes were described previously [37].

Briefly, melanocytes were isolated from human foreskin specimens obtained after circumcision surgery.


Cells were cultured in Hu16 medium (F12 supplemented with 10% fetal bovine serum (FBS), 20 ng/ml

bFGF and 20 mg/ml IBMX) and cultured at 37 ℃ in an incubator with 5% CO2 and 95% humidity. The

cells were used between passages 2 and 5. Melanocytes were seeded at a density of 1×104 cells per well

into 96-well plates, or at a density of 1×105 cells per well into 24 -well plates, or at a density of 3×105

cells per well into 6-well plates and incubated overnight before experiments.

Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood using Ficoll-Paque

density centrifugation. CD8+T cells were then separated from PBMC using Human CD8+ T Cell

Isolation Kit according to the protocol from manufacturer. Both purified CD8+T cells and the human T

lymphoma cell line Jurkat cells were cultured in RPMI-1640 medium supplemented with 100 units/mL

streptomycin, 100 units/mL penicillin, 2 mM gultamine, 1 mM sodium pyruvate, 10 mM nonessential

amino acids, and 10％ FBS. CD8+T cells or Jurkat cells were stimulated for 48 h with PMA (25 ng/mL)

and Ionomycin (1 µM) in the presence IL-2 (10U/mL) before each experiment.

RNA Isolation and quantitative PCR

Total RNA was extracted from melanocytes with SV total RNA purification kit (Promega, Shanghai,

China). Reverse transcript reaction was performed using QuantiTect Reverse Transcription Kit (Qiagen,

Germany). Real time PCR was performed using QuantiFast SYBR Green PCR Kit (Qiagen, Germany).

The expression levels of each gene was normalized against β-actin using the comparative Ct method,

and expressed as percentage of IFN-γ group, with the IFN-γ group as 1. primer sequences were as

follows: CXCL10: forward primer 5’-GTGGCATTCAAGGAGTACCTC-3’, reverse primer 5’-

TGATGGCCTTCGATTCTGGATT-3’; ICAM-1: forward primer 5’-TATGGCAACGACTCCTTC T-

3’, reverse primer 5’-CATTCAGCG TCACCTTGG-3’; MCP-1:forward primer 5’-

TGTCCCAAAGAAGCTGTAGTATTTGT-3’, reverse primer 5’-

TTCTGATCTACTTGGTTCTGGTC-3’; β-actin: forward primer 5’-

ATAGCACAGCCTGGATAGCAACGTAC-3’, reverse primer 5’-

CACCTTCTACAATGAGCTGCGTGTG-3’.


Enzyme-linked immunosorbant assay (ELISA)

Melanocytes were plated into six-well plates and incubated in 37℃ in a humidified incubator at an

atmosphere containing 5% CO2. After being washed with warm PBS, melanocytes were pre-treated with

increasing concentrations of EGCG (0, 10, 20, and 40 µM) and 25 µM AG-490 in Hu16 medium for 1

h, followed by IFN-γ (200 U/ml) stimulation for 48 h. The cell supernatants were then collected, and the

expression levels intercellular adhesion molecule-1 (ICAM-1), monocyte chemotactic protein-1 (MCP-

1), and chemokines CXCL10 were analyzed by ELISA kits (R&D Systems, Minneapolis, USA)

according to the manufacturer’s instructions.

Western blot analysis

Cells were collected and lysed in RIPA buffer (10 mM NaPO4, pH 7.4, 300 mMNaCl, 0.1% SDS, 1%

Nonidet P-40, 1% deoxycholic acid and 2 mM EDTA) with protease inhibitors (Pierce, USA). Aliquots

of 20-30μg of protein from each sample (treated as indicated in the legends) were separated by 8-10%

SDS-PAGE and transferred onto a PVDF membrane (Millipore, Bedford, MA). After blocked with 5%

BSA (Beyotime, China) for 1 h, membrane was incubated with specified antibodies overnight at 4°C

followed by incubation with fluorescent dye-labeled secondary antibodies for 1 h at room temperature

in the dark. The protein immuno-complex was visualized by an Odyssey Infrared Imaging System (LI-

COR, USA). Quantification of band intensity was performed using the quantification software of the

digital imaging system (ChemiDoc™ XRS+, Bio-Rad, USA).

Adhesion assay

Melanocytes were grown to confluence in six-well plates and incubated with or without IFN-γ

(200U/mL) for 24 h. Human T cells (Jurkat cells or purified CD8+T cells) were labeled with 5 µM of

DiO, a fluorescent dye, at 37 ℃, for 5 minutes, and subsequently washed twice by PBS. Labeled T cells

(2×106 cells/well) were then incubated with melanocytes in six-well plates at 37 ℃ for 30 min. Non-


adherent T cells were removed, and plates were gently washed twice with PBS. The numbers of adherent

T cells were counted by four fields per 200×high-power field well using fluorescence microscope.

Statistical analysis

All experiments were performed at least three times in triplicate, with one representative experiment

shown. All experimental data obtained from cultured cells were expressed as mean ± SD. One-way

ANOVA, followed by Student-Newman-Keuls multiple comparison tests, was used to analyze the

statistical significance between groups. P values ＜ 0.05 were considered statistically significant.


Acknowledgments

This study was supported by the Natural Science Foundation of Zhejiang, China (Grant no. Y2111310

and no. LY13H110001), the National Natural Science Foundation of China (grant no. 81271758 and no.

81472887), the Key Scientific Innovation Program of Hangzhou (20122513A02), and the National Key

Clinical Specialty Construction Project of China.


Conflicts of Interest

The authors declare no conflict of interest.


References

1) Bystryn JC., Immune mechanisms in vitiligo.ClinDermatol. 15, 853-861 (1997).

2) van den Wijngaard R.,Wankowicz-Kalinska A., Le Poole C.,Tigges B.,Westerhof W., Das P., Local

immune response in skin of generalized vitiligo patients. Destruction of melanocytes is associated

with the prominent presence of CLA+ T cells at the perilesional site. Lab Invest, 80, 1299-1309.

3) Lili Y., Yi W., Ji Y., Yue S., Weimin S., Ming L., Global activation of CD8+ cytotoxic T lymphocytes

correlates with an impairment in regulatory T cells in patients with generalized vitiligo. PLoS One.

7(5):e37513 (2012).

4) van den Boorn JG., Konijnenberg D., Dellemijn TA., van der Veen JP., Bos JD., Melief CJ., Vyth-

Dreese FA., Luiten RM. Autoimmune destruction of skin melanocytes by perilesional T cells from

vitiligo patients. J Invest Dermatol. 129, 2220-2232 (2009).

5) Ogg GS., Rod Dunbar P., Romero P., Chen JL., Cerundolo V. High frequency of skin-homing

melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med. 188, 1203-1208

(1998).

6) Shaffrali F., Gawkrodger D., Management of vitiligo. ClinExpDermatol. 25, 575-579 (2000).

7) Kumari J., Vitiligo treated with topical clobetasol propionate. Arch Dermatol. 120, 631-635 (1984).

8) Kalaiselvi P., Rajashree K., BharathiPriya L., Padma VV., Cytoprotective effect of epigallocatechin-3-

gallate against deoxynivalenol-induced toxicity through anti-oxidative and anti-inflammatory

mechanisms in HT-29 cells. Food ChemToxicol. 56, 110-118 (2013).

9) Van Aller GS., Carson JD., Tang W., Peng H., Zhao L., Copeland RA., Tummino PJ, Luo L.,

Epigallocatechingallate (EGCG), a major component of green tea, is a dual phosphoinositide-3-

kinase/mTOR inhibitor. BiochemBiophys Res Commun. 406,194-199 (2011).

10) Zhu Y., Wang S., Lin F., Li Q., Xu A., The therapeutic effects of EGCG on vitiligo. Fitoterapia. 99,

243-251 (2014).

11) Darnell JE Jr., STATs and gene regulation. Science. 277, 1630-1635 (1997).


12) Ghoreschi K., Laurence A., O'Shea JJ., Janus kinases in immune cell signaling.Immunol Rev. 228,

273-287 (2009).

13) Hsu L., Armstrong AW., JAK inhibitors: treatment efficacy and safety profile in patients with

psoriasis. J Immunol Res. 2014, 283617 (2014).

14) Ortiz-Ibáñez K., Alsina MM., Muñoz-Santos C., Tofacitinib and other kinase inhibitors in the

treatment of psoriasis.Actas Dermosifiliogr. 104, 304-310 (2013).

15) Fridman JS., Scherle PA., Collins R., Burn T., Neilan CL., Hertel D., Contel N., Haley P., Thomas B.,

Shi J., Collier P., Rodgers JD., Shepard S., Metcalf B., Hollis G., Newton RC., Yeleswaram S.,

Friedman SM., Vaddi K., Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous

inflammation. J Invest Dermatol. 131, 1838-1844 (2011).

16) Chen JT., Liang JB., Chou CL., Chien MW., Shyu RC., Chou PI., Lu DW., Glucosamine sulfate

inhibits TNF-alpha and IFN-gamma-induced production of ICAM-1 in human retinal pigment

epithelial cells in vitro. Invest Ophthalmol Vis Sci. 47, 664-672 (2006).

17) Roebuck KA., Finnegan A., Regulation of intercellular adhesion molecule-1 (CD54) gene expression.

J LeukocBiol. 66, 876-888 (1999).

18) Wang S., Zhou M., Lin F., Liu D., Hong W., Lu L., Zhu Y., Xu A., Interferon-γ induces senescence

in normal human melanocytes. PLoS One. 9(3), e93232 (2014).

19) Chatterjee S., Eby JM2., Al-Khami AA1., Soloshchenko M1., Kang HK2., Kaur N1., Naga OS1.,

Murali A1., Nishimura MI3., Le Poole IC2., Mehrotra S1., A quantitative increase in regulatory T

cells controls development of vitiligo. J Invest Dermatol. 134, 1285-1294 (2014).

20) Shi F., Erf GF., IFN-γ, IL-21, and IL-10 co-expression in evolving autoimmune vitiligo lesions of

Smyth line chickens. J Invest Dermatol. 132, 642-649 (2012).

21) Harris JE., Harris TH., Weninger W., Wherry EJ., Hunter CA., Turka LA., A mouse model of vitiligo

with focused epidermal depigmentation requires IFN-γ for autoreactive CD8T-cell accumulation in

the skin. J Invest Dermatol. 132, 1869-1876 (2012).


22) al Badri AM1., Foulis AK., Todd PM., Gariouch JJ., Gudgeon JE., Stewart DG., Gracie JA., Goudie

RB., Abnormal expression of MHC class II and ICAM-1 by melanocytes in vitiligo. J Pathol. 169,

203-206 (1993).

23) Li YL., Yu CL., Yu HS., IgG anti-melanocyte antibodies purified from patients with active vitiligo

induce HLA-DR and intercellular adhesion molecule-1 expression and an increase in interleukin-8

release by melanocytes. J Invest Dermatol. 115, 969-973 (2000).

24) Rashighi M., Agarwal P., Richmond JM., Harris TH., Dresser K., Su MW., Zhou Y., Deng A., Hunter

CA., Luster AD., Harris JE., CXCL10 is critical for the progression and maintenance of

depigmentation in a mouse model of vitiligo. SciTransl Med. 6(223), 223ra23 (2014).

25) Crane IJ., McKillop-Smith S., Wallace CA., Lamont GR., Forrester JV., Expression of the chemokines

MIP-1alpha, MCP-1, and RANTES in experimental autoimmune uveitis. Invest Ophthalmol Vis Sci.

42, 1547-1552 (2001).

26) Elner SG., Elner VM., Bian ZM., Lukacs NW., Kurtz RM., Strieter RM., Kunkel SL., Human retinal

pigment epithelial cell interleukin-8 and monocyte chemotactic protein-1 modulation by T-

lymphocyte products. Invest Ophthalmol Vis Sci. 38:446-455 (1997).

27) Berencsi K., Rani P., Zhang T., Gross L., Mastrangelo M., Meropol NJ., Herlyn D., Somasundaram

R., In vitro migration of cytotoxic T lymphocyte derived from a colon carcinoma patient is dependent

on CCL2 and CCR2.J Transl Med. 9, 33 (2011).

28) Kamimura D., Ishihara K., Hirano T., IL-6 signal transduction and its physiological roles: the signal

orchestration model. Rev PhysiolBiochemPharmacol. 149:1-38 (2003).

29) Toosi S.,Orlow SJ., Manga P., Vitiligo-inducing phenols activate the unfolded protein response in

melanocytes resulting in upregulation of IL6 and IL8. J Invest Dermatol. 132, 2601-2609 (2012).

30) Marino M1., Scuderi F., Provenzano C., Scheller J., Rose-John S., Bartoccioni E., IL-6 regulates

MCP-1, ICAM-1 and IL-6 expression in human myoblasts. J Neuroimmunol. 196, 41-48 (2008).

31) Chen SC., Chang YL., Wang DL., Cheng JJ., Herbal remedy magnolol suppresses IL-6-induced

STAT3 activation and gene expression in endothelial cells. Br J Pharmacol. 148, 226-232 (2006).


32) Gilhar A., Aizen E., Ohana N., Etzioni A., Vitiliginousvs pigmented skin response to intradermal

administration of interferon gamma. Arch Dermatol. 129, 600-604 (1993).

33) Lebedeva T., Dustin ML.,Sykulev Y., ICAM-1 co-stimulates target cells to facilitate antigen

presentation. CurrOpinImmunol. 17, 251-258 (2005).

34) Norris DA., Cytokine modulation of adhesion molecules in the regulation of immunologic cytotoxicity

of epidermal targets. J Invest Dermatol. 95(6 Suppl), 111S-120S (1990).

35) Anikeeva N., Somersalo K., Sims TN., Thomas VK., Dustin ML., Sykulev Y., Distinct role of

lymphocyte function-associated antigen-1 in mediating effective cytolytic activity by cytotoxic T

lymphocytes. ProcNatlAcadSci U S A. 102, 6437-6442 (2005).

36) Koneru M., Monu N., Schaer D., Barletta J., Frey AB., Defective adhesion in tumor infiltrating CD8+

T cells.J Immunol. 176, 6103-6111 (2006).

37) Hong WS., Hu DN., Qian GP., McCormick SA., Xu AE., Ratio of size of recipient and donor areas

in treatment of vitiligo by autologous cultured melanocyte transplantation. Br J Dermatol. 165, 520-

525 (2011).


Figure Legends

Fig. 1 Inhibition of EGCG on Jak2 in vitro

(A) Molecular structures of EGCG and its derivative AcEGCG. (B) IC50 profiling results of EGCG,

AcEGCG and pan-kinase inhibitor staurosporine (STS) for JAK2 kinase inhibition. (C) Interaction mode

between EGCG and the binding pocket of JAK2.

Fig. 2 EGCG inhibited IFN-γ-induced phosphorylation of JAK2/STATs in human melanocytes

The primary human melanocytes were exposed to EGCG at the concentration of 0, 10, 20, 40 µM for

1h. Then, IFN-γ was then administered in a concentration of 200 U/ml for 1h. Whole cell lysates were

subjected to SDS-PAGE and analyzed by western blot with corresponding antibodies.

Fig.3 EGCG dose-dependently inhibited ICAM-1, CXCL10, and MCP-1 production in IFN-γ-stimulated

melanocytes

Primary human melanocytes were pre-treated with various concentrations of EGCG (0, 10, 20, and 40

μM) or JAK2 specific inhibitor AG490 (25 μM) for 1 h before incubated with 200U/mL of IFN-γ. Total

RNA was extracted from melanocytes at 24 h after IFN-γ treatment, and qRT-PCR was performed to

measure the mRNA expression of ICAM-1, CXCL10 and MCP-1. The expression level of each gene

was normalized against β-actin using the comparative Ct method. The level of mRNA expression was

expressed as fold-change relative to that in IFN-γ group (IFN-γ group as 1). Supernatants were collected

at 48 h after IFN-γ treatment, ICAM-1, CXCL10, and MCP-1 concentration was measured by ELISA.

The values shown represent the mean±SD of three independent experiments. * P＜0.01, ** P＜0.01,

*** P＜0.01 vs. IFN-γ group.

Fig. 4 Effect of EGCG on CD11a, CXCR3 and CCR2 expression in human T cells

Human T cells were activated for 48 h with PMA (25 ng/mL) and Ionomycin (1 µM) in the presence IL-

2 (10U/mL) before incubation with various concentrations of EGCG or AG-490 for 24 h. Western blot


analysis was used to detect protein expressions of CD11a, CXCR3 and CCR2. β-actin was probed as

loading control. (A) Effect of EGCG on CD11a, CXCR3 and CCR2 expression in Jurkat cells. (B) Effect

of EGCG on CD11a, CXCR3 and CCR2 expression in purified CD8+T cells from PBMC. Results from

three experiments were quantified by densitometry (bottom panels). * P＜0.01, ** P＜0.01, vs. control

group.

Fig. 5 EGCG blocks adhesion of human T cells to melanocytes

Primary human melanocytes (MC) were cultured with various combination of IFN-γ (200 U/mL) and

EGCG (40 µM) treatment for 24 h. Human T cells (Jurkat cells (A) or purified CD8+T cells from PBMC

(B)) were incubated without or with 40µM EGCG for 24 h, and then labeled with 5 µM of DiO before

the adhesion assay. The numbers of adherent T cells were counted by four fields per 200×high-power

field well using fluorescence microscope. The values shown represent the mean ± SD of three

independent experiments. *P＜0.01 verse control group in which melanocytes (MC) were untreated by

IFN-γ. #P＜0.05 verse group in which melanocytes were treated with IFN-γ alone and T cells (Jurkat or

CD8+T cells) were untreated.


Fig.1


Fig.2


Fig.3


Fig.4


Fig.5


International Journal of Molecular Sciences - J-STAGE Home

Documents

Transcript of International Journal of Molecular Sciences - J-STAGE Home